Anal Cancer: An Overview
TEST_code
|
CME Activity Information |
|
Release Date: |
May 23, 2007 |
|
Date Credit Expires: |
May 23, 2009 |
|
Time to Complete: |
1 hour |
|
Medium: |
Internet Online |
|
*Click here
to learn more about our review process. |
Instructions for Participation
- Read the following information before beginning the educational activity
and click the "Take this course" link at the bottom of the page
- Study the educational activity
- Complete the CME quiz and evaluation
- After successful completion of the CME quiz and evaluation, you will receive
the credit or participation certificate
*The CME quiz and evaluation must be completed by May 23, 2009, in order
to receive the credit or participation certificate.
Target Audience
Physicians who wish to advance their current knowledge of clinical cancer medicine
in gastrointestinal cancer and are involved in providing patient care in a cancer
care environment.
Learning Objectives
After completing this course, the reader should be able to:
- Discuss the epidemiology of and the risk factors for anal cancer.
- Outline standard treatment for anal cancer and understand its complications.
- Understand the issues related to treating HIV-positive patients with anal
cancer.
Accreditation and Credit Designation
This activity has been planned and implemented in accordance
with the Essential Areas and policies of the Accreditation Council for Continuing
Medical Education (ACCME) through the joint sponsorship of the National Institutes
of Health Foundation for Advance Education in the Sciences (NIH/FAES) and The
Oncologist. The NIH/FAES is accredited by the ACCME to provide continuing
medical education for physicians.
The NIH/FAES designates this educational activity for a maximum of 1.00 AMA
PRA Category 1 Credit™. Physicians should only claim credit commensurate
with the extent of their participation in the activity.
Disclosure Policy
In compliance with the ACCME Standards of Commercial Support, it is the policy of the NIH/FAES to ensure balance,
independence, objectivity, and scientific rigor in all of its educational activities
and to include information free of commercial bias and based on the best evidence
available. All individuals in a position to influence the content of this activity
have disclosed relevant financial interests or relationships of their own, their
spouse/partner, or their worksite, with manufacturers or providers of commercial
products, services, technology, or programs; and disclosed relationships with
current non-governmental supporters of the activity. The faculty and planners
have disclosed that they have no relevant commercial relationships.
All information is submitted and reviewed and found to be scientifically rigorous,
based on the best available evidence, fair and balanced, and free of commercial
bias. All the recommendations involving clinical medicine in this CME activity
are based on evidence that is accepted within the profession of medicine as
adequate justification for their indications and contraindications in the care
of patients. All scientific research referred to, reported or used in CME in
support or justification of a patient care recommendation conforms to the generally
accepted standards of experimental design, data collection and analysis.
Any potential conflicts of interests are resolved via The Oncologist's anonymous
peer review process
All manuscripts are reviewed by the Editorial Board with ad hoc assistance from
two or more external experts in the field. All final publication
decisions are made by the Editorial Board. The acceptance of a manuscript is
based on its originality and importance to the field as assessed by the Editors.
Author Disclosure(s)
Hope E. Uronis, M.D.
Credentials: Medical Instructor, Department of Medicine, Division
of Medical Oncology, Duke University Medical Center, Durham,
North Carolina, USA.
Disclosures: The author has indicated no relevant commercial
relationships.
Johanna C. Bendell, M.D.
Credentials: Assistant Professor, Department of Medicine, Division of Medical
Oncology, Duke University Medical Center, Durham, North Carolina, USA.
Disclosures: The author has served as an oxaliplatin consultant for sanofi-aventis.
Section Editors Disclosures
Patrick Johnston, M.D., Ph.D., and Peter J. O’Dwyer, M.D., have disclosed no financial relationships relevant to the content of this article.
CME Activity Director Disclosure
Frank M. Balis, M.D., CME Activity Director, Clinical Director, National Cancer Institute, has disclosed no financial relationships relevant to the content of this article.
Independent Peer Reviewers and Staff Managers Disclosures
No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers or staff managers.
Commercial Support
Non-governmental supporters of this activity: AstraZeneca, Bristol-Myers
Squibb Oncology, Pfizer, and sanofi-aventis
Hardware/Software Requirements
The Oncologist CME Online supports
the following browsers: Current production versions of Opera, Safari, Firefox,
Lynx and Mozilla; Netscape 6.1 and above, and Explorer 6.0 and above. The Macintosh
version of Explorer was discontinued in June 2003, and is not supported.
Other Links
Disclaimer
Privacy statement
Correspondence
The Oncologist CME Online
c/o AlphaMed Press
318 Blackwell Street, Suite 260
Durham, North Carolina 27701
Phone: (919) 680-0011
Fax: (919) 680-4411
Email: angela.davies{at}ucdmc.ucdavis.edu